{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:02Z","timestamp":1781585642390,"version":"3.54.5"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The treatment of hepatocellular carcinoma (HCC) in Japan is driven by locoregional therapies (LRTs). However, the treatment landscape in the era of systemic targeted therapies and immunotherapies is not well understood. We investigated the real\u2010world treatment patterns of combined LRT and systemic therapy in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed analyses of the Medical Data Vision (MDV) database using data for patients with a recorded diagnosis of HCC and at least one record of a first LRT (January 1, 2020\u2013December 31, 2022; hepatectomy, transarterial chemoembolization [TACE], radiation therapy [RT], ablation, or hepatic arterial infusion chemotherapy [HAIC]) after the record of HCC diagnosis. We examined the use of preceding systemic therapy (PSysT), maintenance treatment (MT), and next treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 15,285 patients, hepatectomy, TACE, RT, ablation, and HAIC were performed in 4506, 6389, 991, 3351, and 48 patients, respectively. Few patients received PSysT, including lenvatinib (by LRT: 0.93%\u201312.50%) and atezolizumab + bevacizumab (by LRT: 0.29%\u20134.94%). Only TACE with PSysT increased slightly during the study period. MT was infrequent. Cumulative incidence of next treatment at 6\u2009months varied by type of first LRT, ranging from 6.61% following hepatectomy to 45.06% following HAIC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LRT alone remained the standard approach for treating HCC in Japan in 2020\u20132022. The type and duration of therapies used before or after first LRT varied, suggesting a lack of standardized protocols. A clear strategy is needed to evaluate and establish appropriate LRT\u2010based combination therapies for HCC, considering the unmet medical needs identified in this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71787","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:11:53Z","timestamp":1778904713000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential Use of Systemic Therapy With Locoregional Therapy for Hepatocellular Carcinoma in Japan: Analyses of Real\u2010World Data Based on a Health Claims Database"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-5267","authenticated-orcid":false,"given":"Junichi","family":"Shindoh","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery Toranomon Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"Medical Department AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Takashima","sequence":"additional","affiliation":[{"name":"Medical Department AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawai","sequence":"additional","affiliation":[{"name":"Medical Department AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Nishida","sequence":"additional","affiliation":[{"name":"Medical Department AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-1213","authenticated-orcid":false,"given":"Hiroshi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Medical Department AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_14_4_1","volume-title":"Statistics by Cancer Site: Liver","author":"Cancer Information Service, National Cancer Center, Japan","year":"2025"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13953"},{"key":"e_1_2_14_6_1","volume-title":"JSH HCC Guidelines 2021","author":"Japan Society of Hepatology","year":"2025"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13892"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534\u2010009\u20100168\u20105"},{"key":"e_1_2_14_9_1","volume-title":"Report on the 24th National Primary Liver Cancer Follow\u2010up Survey (2016\u20102017)","author":"Japan Liver Cancer Association","year":"2025"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.486"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000531377"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i2.100505"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2022.2059581"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5403"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010023\u201011302\u20106"},{"key":"e_1_2_14_16_1","unstructured":"JRCT \u201cLenvatinib Plus Cisplatin Hepatic Arterial Infusion Chemotherapy for Borderline Resectable Hepatocellular Carcinoma: A Multicenter Phase II Study (LEOPARD\u2010Neo). Jrcts031230128 \u201d(2025) https:\/\/jrct.mhlw.go.jp\/en\u2010latest\u2010detail\/jRCTs031230128."},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.236"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.851"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270\u2010021\u201003031\u20109"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)02551\u20100"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010020\u201000240\u20103"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20200288"},{"key":"e_1_2_14_23_1","unstructured":"Japan Society for Pharmacoepidemiology \u201cDatabases Available for Pharmacoepidemiology Researches in Japan \u201d(2024) https:\/\/www.jspe.jp\/wp\u2010content\/uploads\/2024\/10\/Table\u2010of\u2010DB\u2010survey\u2010results_240925.pdf."},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)00198\u20109"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2279"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010021\u201000234\u20104"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(21)00427\u20101"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/20450923.2025.2530377"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1504917"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.784"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000538627"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000518584"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010024\u201000868\u20100"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)02575\u20103"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000538558"},{"key":"e_1_2_14_36_1","volume-title":"JSH HCC Guidelines 2017","author":"Japan Society of Hepatology","year":"2017"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13411"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102021\u2010059779"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000531820"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2019.0021n"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)30207\u20101"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.09.052"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2023_230806N413"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.10.040"},{"key":"e_1_2_14_45_1","volume-title":"Evaluate Durvalumab and Tremelimumab +\/\u2212 Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD\u20103). NCT05301842","author":"AstraZeneca","year":"2026"},{"key":"e_1_2_14_46_1","volume-title":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma. NCT04712643","author":"Hoffmann\u2010La Roche","year":"2026"},{"key":"e_1_2_14_47_1","volume-title":"A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans\u2010Arterial Chemoembolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74w). NCT04340193","author":"Bristol\u2010Myers Squibb","year":"2025"},{"key":"e_1_2_14_48_1","unstructured":"The Clatterbridge Cancer Centre NHS Foundation Trust \u201cNivolumab in Combination with TACE\/TAE for Patients with Intermediate Stage HCC (TACE\u20103). NCT04268888 (National Library of Medicine 2025) \u201dhttps:\/\/clinicaltrials.gov\/study\/NCT04268888."},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010024\u201012940\u20100"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:13:16Z","timestamp":1781583196000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cam4.71787"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71787","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71787"}}